Oracle's Two-Front War: A Record $638 Billion Backlog Versus a Balance Sheet Under Siege
Published on 08/10/2026 at 18:22 | Redaktion boerse-global.de
The gap between Oracle's commercial momentum and its financial architecture has rarely yawned so wide. Even as the software giant stacks up cloud contracts at a dizzying pace, the credit markets are pricing its debt at levels normally reserved for companies on the brink of junk status — and the most famous short-seller on Wall Street has just re-entered the fray.
The Bear Case: Burry's Bet and a Founder's Entanglements
Michael Burry, the investor who became a household name after the 2008 financial crisis, opened a fresh short position in Oracle on August 6 at $144.63 per share. His stated rationale: mounting leverage risks tied to off-balance-sheet obligations. The move came just one day after he closed a previous put position on the stock at what he described as a "substantial" profit — only to immediately pivot back to betting against the company.
Burry's language is characteristically blunt. He describes Oracle as being "in a bit of a bind," warning that a potential collapse could become "the most expensive tragic case in a very long time" — a "Homeric own goal," in his words.
His skepticism centers partly on founder Larry Ellison's sprawling financial commitments. Ellison holds roughly 1.158 billion Oracle shares, representing about 40.6 percent of all outstanding stock, and collected an estimated $579 million from the most recent quarterly dividend of $0.50 per share. Yet in late July, he signed an irrevocable personal guarantee of $40.4 billion tied to the equity financing of Paramount Skydance in its battle for Warner Bros. Discovery — while pledging not to touch his Oracle trust during that period. Capital tied up in external takeover fights is capital that cannot be deployed to support Oracle's own ambitions.
The cost-cutting narrative adds another layer. Oracle has shed 21,000 positions over the past year, roughly 13 percent of its workforce, shrinking full-time headcount from 162,000 to 141,000 employees — belt-tightening that seems at odds with the company's pledge of more than $20 billion in investments for 2026.
Should investors sell immediately? Or is it worth buying Oracle?
The Credit Market's Verdict
The bond market has been sending its own warning signals. Reuters reported on August 4 that Oracle is "on the verge of a junk rating," as investors reassess the debt-financed AI expansion. The company's bonds have come under pressure, with yields climbing to roughly 7 to 8 percent.
The contrast with Big Tech peers is stark: Alphabet and Amazon bonds yield between 2.5 and 3.5 percent, according to Reuters — a reflection of just how much of a risk premium investors now demand for holding Oracle debt. The company has become a central case study in the broader debt boom among AI hyperscalers: the more aggressively a company invests in data centers and chips, the more closely creditors scrutinize its balance sheet. For Oracle, creditworthiness increasingly hinges on how quickly its multibillion-dollar investments translate into cash flow.
That is precisely where the tension lies. The company's Remaining Performance Obligations stood at $638 billion as of August 3 — an enormous backlog to work through in the coming years. Yet free cash flow came in at negative $23.7 billion. The combination explains why investors oscillate between confidence and concern: the backlog promises future revenue, but the coffers are currently strained by heavy AI-related investment.
The Bull Case: A Pipeline That Keeps Growing
Dismissing the risk side entirely, however, means overlooking the sheer force of Oracle's operational news flow. In late July, the stock jumped more than 8 percent after Oracle announced an expanded partnership with Google Cloud — customers gain access to Gemini models through the AI Agent Studio for Fusion Applications and NetSuite, choosing between the lean Gemini 3.1 Flash-Lite or the more powerful Gemini 3.5 Flash.
Early August brought a contract from CACI International, which joins Baker Tilly and Deloitte as technology partners on a ten-year deal to modernize the federal HR systems of the U.S. Office of Personnel Management — a package worth nearly $400 million. Running in parallel is the up-to-$7 billion, ten-year contract with the U.S. Department of Defense, where CIO Kirsten Davies has projected at least $441 million in savings for taxpayers.
Oracle Health continues to expand as well. When Canada's Baycrest Hospital joined a shared electronic health records rollout with Sunnybrook in Ontario, the stock responded with a 9.22 percent gain. Underpinning all of this is a cloud backlog of $638 billion, with the infrastructure business growing 93 percent in the latest period.
A Rally Meets a Lowered Target
On August 3, a short-lived rally took hold: the stock climbed 5.6 percent intraday as investors focused on the company's ability to convert its billion-dollar order mountain into payment streams, rather than dwelling on the near-term cash flow gap. In German trading, Oracle shares were recently quoted at €129.42, up 1.83 percent from Friday's close, with a 5.00 percent recovery over the past seven trading sessions.
Oracle at a turning point? This analysis reveals what investors need to know now.
The analyst community has responded with a mix of caution and conviction. UBS cut its price target for Oracle to $245 from $285 on Friday but maintained a "Buy" rating — trimming expectations while signaling that the recent share slide appears overdone, even as balance sheet risks are acknowledged.
Institutional positioning tells a similarly split story. Eastern Bank increased its Oracle stake by 2.0 percent in the second quarter, holding 281,261 shares. Meanwhile, Franklin Street Advisors was disclosed on Monday to have sold Oracle shares, though the size of the transaction was not revealed. The opposing moves underscore how differently institutional investors currently weigh the balance between AI growth opportunities and leverage risk.
The Verdict Ahead
On Friday, the stock closed at €127.10, up 3.12 percent over seven days — a tentative sign of life after a year in which the shares have lost 41.64 percent and still trade 56.89 percent below their record high from September 10, 2025.
The core question — for equity investors and bondholders alike — remains whether Oracle can convert its colossal order backlog into real cash flow quickly enough to service the debt load from its AI investments, or whether creditors will strip the company of its current credit rating. The next test comes with quarterly results on September 7, where consensus expectations call for earnings of $1.77 per share on revenue of $19.52 billion. For now, neither the bull nor the bear narrative holds undisputed sway — and anyone watching Oracle would do well to track both sides of the story, not just the louder one.
Ad
Oracle Stock: New Analysis - 10 August
Fresh Oracle information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
